

ONCOLOGY REQUISITION FORM

GENETIC ANALYSIS OF SOLID TUMORS

Patient Identification (mandatory)

Name: _____

Gender: F M

Date of birth: ____/____/____

Identification number: _____

GenoMed use only:
Post label(s)

Conferred by:

CLINICAL DATA AND DIAGNOSIS (describe therapy, if any): _____

Initial Diagnosis

Relapse / Progressive Disease

Referring Doctor (mandatory)

Name (or print label): _____ ID number: _____

Telephone or email: _____ Hospital: _____ Service: _____

Do you authorize the report to sent by email? Yes No If yes, please write your **institutional email** address:

Informed Consent (to be filled by the referring doctor):

I hereby declare that the patient informed consent for diagnosis was obtained.

Yes No

I hereby declare that the patient informed consent for investigation was obtained.

Yes No

Referring doctor signature: _____

Date: ____/____/____

Specimen Details

Paraffin block or Sections*

- We ask a pathology report where possible, for correctly interpret test results.
- When sending sections macrodissection is recommended if tumor cell percentage is lower than 20-30%. To perform a correct CNV analysis, the percentage of neoplastic cells in the sample should be higher than a 50%.
- **Sample Rejection Conditions:** Decalcified specimens. Specimens with tumorous tissue.

Exam nº: _____ Resection/Biopsy Date: _____

Surgical resection Biopsy Fine Needle Biopsy cell-block Other _____

Macrodissection Yes No

% Neoplastic Cells: _____

Any other relevant information (main contaminants, blood, necrosis or other):

Pathologist: _____ Hospital: _____

Telephone or email: _____

*Sections – Verify in each the code that indicates the necessary thickness and quantity of sections (in multiple requests one tube per thickness is enough) (pedidos múltiplos enviar um tubo por espessura):

(1) 6x20 µm
(2) 10x10 µm

(3) 3x50 µm
(4) 5x10 µm

(5) 5x5 µm
(6) Tumour tissue 10x10µm + Blood

Contact Persons: Dra. Ana Carla Sousa (assousa@medicina.ulisboa.pt)/ Dra. Sónia Santos (soniasantos@medicina.ulisboa.pt) Ext. 47301

IMP 72_v.07

Pág. 1/3

ONCOLOGY REQUISITION FORM

GENETIC ANALYSIS OF SOLID TUMORS

Available Tests

Lung Cancer

- Lung by NGS (1)** 34900

Hotspots: AKT1; ALK; BRAF; DDR2; EGFR; FGFR2; FGFR3; ERBB2 (HER2); ERBB3 (HER3); ERBB4 (HER4); KRAS; MAP2K1; MET; NRAS; PIK3CA; RET; ROS1
Fusion drivers: ALK; FGFR1; FGFR2; FGFR3; MET (skipping exão 14); NTRK1; NTRK2; NTRK3; ROS1; RET
CNVs^a: EGFR; FGFR1; FGFR2; ERBB2 (HER2); KRAS; MET

- BRAF** (Val600) (2) 36314
 ALK (2p23) rearrangements by FISH (3) 31710
 ROS1 (6q22) rearrangements by FISH (3) 31710

Colorectal Cancer

- CCR by NGS (1)** 34900

Hotspots: BRAF; EGFR; ERBB2 (HER2); ERBB3 (HER3); KRAS; NRAS; PIK3CA
Fusion drivers: NTRK1; NTRK2; NTRK3
CNVs^a: ERBB2 (HER2); MET

- KRAS**, with **NRAS** and **BRAF** (Val600) reflex testing (4) 34900
 BRAF (Val600) (2) 36314
 MSI - Microsatellite Instability (6) 34650
 MLH1 promoter hypermethylation (2) 34900

Breast Cancer

- PIK3CA** (5) 34900
 FGFR1 (8p12) and **FGFR2** (10q26) amplification by FISH (3) 2x31710

Bladder Cancer

- Bladder by NGS (1)** 34900

Hotspots: AKT1; ALK; BRAF; DDR2; EGFR; FGFR2; FGFR3; ERBB2 (HER2); ERBB3 (HER3); ERBB4 (HER4); KRAS; MAP2K1; MET; NRAS; PIK3CA; RET; ROS1
Fusion drivers: ALK; FGFR1; FGFR2; FGFR3; MET (skipping exão 14); NTRK1; NTRK2; NTRK3; ROS1; RET
CNVs^a: EGFR; FGFR1; FGFR2; ERBB2 (HER2); KRAS; MET

Endometrial Cancer

- POLE** (exons 9, 11, 13, and 14) (2) 34900
 MSI - Microsatellite Instability (6) 34650
 MLH1 promoter hypermethylation (2) 34900
 TP53 (2) 34900

Melanoma

- BRAF** (Val600) (2) 36314
 KIT (exon 11) (2) 34847
 NRAS (codons 12, 13 and 61) (2) 34900

GIST

- KIT** (exons 9 and 11) (2) 2x34847
 KIT (exons 9, 11, 13, 14 and 17) (2) 5x34847
 PDGFRA (exons 12, 14 and 18) (2) 34900

Brain Cancer

- BRAF** (Val600) (2) 36314
 H3F3A (K27M and G34R/V) (2) 34900
 HIST1H3B (K27M) (2) 34900
 IDH1 (exon 4) (2) 34900
 IDH2 (exon 4) (2) 34900
 TERT promoter mutations (C228T and C250T) (2) 34900
 MGMT Promotor Methylation (2) 36312
 1p36 and **19q13** deletions by FISH (3) 2x31710
 RELA (11q13) rearrangements by FISH (3) 31710
 EGFR (7p12) amplification by FISH (3) 31710
 PTEN (10q23.31) deletion by FISH (3) 31710
 BRAF (7q34) rearrangements by FISH (3) 31710 (BRAF-KIAA1549 fusion and variants)
 CDKN2A (9p21) deletion by FISH (3) 31710

Other Tumours

- Biomarkers panel for Solid Tumors by NGS (1)** 34900

Mutações (Hotspots - 35 genes): AKT1; ALK; AR; BRAF; CDK4; CTNNB1; DDR2; EGFR; ERBB2 (HER2); ERBB3 (HER3); ERBB4 (HER4); ESR1; FGFR2; FGFR3; GNA11; GNAQ; HRAS; IDH1; IDH2; JAK1; JAK2; JAK3; KIT; KRAS; MAP2K1 (MEK1); MAP2K2 (MEK2); MET; MTOR; NRAS; PDGFRA; PIK3CA; RAF1; RET; ROS1; SMO
CNVs^a (19 genes): ALK; AR; BRAF; CCND1; CDK4; CDK6; EGFR; ERBB2 (HER2); FGFR1; FGFR2; FGFR3; FGFR4; KIT; KRAS; MET; MYC; MYCN; PDGFRA; PIK3CA
Fusion drivers: (23 genes): ABL1; AKT3; ALK; AXL; BRAF; EGFR; ERBB2 (HER2); ERG; ETV1; ETV4; ETV5; FGFR1; FGFR2; FGFR3; MET; NTRK1; NTRK2; NTRK3; PDGFRA; PPARG; RAF1; RET; ROS1

- Her-2/neu** amplification by FISH (3) 31710
 MSI - Microsatellite Instability (6) 34650
 PIK3CA (5) 34900
 NTRK1, NTRK2, NTRK3 rearrangements by NGS (1) 34900

a – To a correct CNV analysis the percentage of neoplastic cells in the sample should be higher than a 50%.

Informed Consent (mandatory - to be filled by the patient)

I hereby declare that I have read the Privacy Policy of GenoMed® - Diagnósticos de Medicina Molecular, S.A., available at <https://genomed.pt/en/privacy-and-cookies-policy/> and I give my consent to the processing of the personal data. Agree Not agree

I also declare to authorize the collection of mine/my _____ [affiliation], _____ [name], born on ____/____/_____, to the execution of the genetic testing described above, whose purposes and limitations were explained by the aforementioned physician. Herewith I declare that I have been informed about the consequences resulting from the teste results. I agree that the sample may be stored in order to allow repetition of the tests or further related tests at GenoMed or authorized partners around the world. The data/test results are subject to medical confidentiality and should only be disclosed to family members or other physicians with my permission. I am entitled to revoke this consent at any time. Agree Not agree

I also declare that the data/test results may be used in scientific investigations and publications in an anonymized form when and only approved by the Ethics Committee. Agree Not agree
(According to the Direction of General Health Standard nº 015/2013 updated.)

Patient's Signature:

Date: ____/____/____

Contact Persons: Dra. Ana Carla Sousa (assousa@medicina.ulisboa.pt)/ Dra. Sónia Santos (soniasantos@medicina.ulisboa.pt) Ext. 47301

IMP 72_v.07

Pág. 2/3

ONCOLOGY REQUISITION FORM GENETIC ANALYSIS OF SOLID TUMORS

